Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1986 results about "Trifluoroacetic acid" patented technology

Trifluoroacetic acid (TFA) is an organofluorine compound with the chemical formula CF₃CO₂H. It is a structural analogue of acetic acid with all three of the acetyl group’s hydrogen atoms replaced by fluorine atoms and is a colorless liquid with a vinegar like odor. TFA is a stronger acid than acetic acid, having an acid ionisation constant that is approximately 34,000 times higher, as the highly electronegative fluorine atoms and consequent electron-withdrawing nature of the trifluoromethyl group weakens the oxygen-hydrogen bond (allowing for greater acidity) and stabilises the anionic conjugate base. TFA is widely used in organic chemistry for various purposes.

Prion-free collagen and collagen-derived products and implants for multiple biomedical applications; methods of making thereof

The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree. The molecules of FA, and most importantly of TFA, remained within collagen. Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110° C. for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products. Finally, prolonged treatment with TFA provides a transparent collagen, which transparency is further enhanced by adding glycosaminoglycans or proteoglycans, particularly hyaluronic acid. All the above treatments could offer a safe and biocompatible collagen-derived material for diverse biomedical uses, by providing a virus or prion-free product.
Owner:UNIV LAVAL

Hyper-branched polycarboxylate high-efficiency water reducing agent and preparation method thereof

The invention relates to a hyper-branched polycarboxylate high-efficiency water reducing agent and a preparation method thereof. The water reducing agent is prepared by polymerizing one of tert-butyl acrylate and methyl tert-butyl acrylate with sodium methyl-acryl sulfonate and allyl polyethenoxy ether to form a copolymer main chain, and then performing condensation polymerization on one of acrylic acid and methacrylic acid with ethylene diamine to form a hyper-branched polyamide structure which is grafted to two ends of the main chain. The preparation method comprises the following steps: (1) preparing the sodium methyl-acryl sulfonate into solution with DMF, and heating the solution in a nitrogen atmosphere; (2) dissolving the other two monomers and an initiating agent into the DMF to prepare mixed solution, and dripping the mixed solution into the step (1) to react for 1 to 20 hours; (3) adding a condensating agent CDI after the reaction and performing condensation reaction by using N-methyl morpholine as an organic base, the ethylene diamine and the acrylic acid as the monomers and the DMF as a solvent; and (4) performing vacuum distillation to remove the residual monomers and the solvent, and refluxing for 2 to 5 hours by using methylene chloride solution of trifluoroacetic acid to obtain the water reducing agent. The hyper-branched polycarboxylate water reducing agent has the advantages of low admixture, high water reducing rate, small slump loss, good compatibility with cement, no corrosivity to steel bars, strong frost resistance and the like.
Owner:厦门路桥翔通建材科技有限公司 +1

Tulathromycin intermediate and preparation method thereof, as well as preparation method of tulathromycin

The invention provides a tulathromycin intermediate, a preparation method of the tulathromycin intermediate, and a preparation method of the tulathromycin. The preparation method of the tulathromycin has the advantages of mild condition, convenience for operation, and low cost. The preparation method of the tulathromycin comprises the following steps of: using azithromycin A as a raw material; protecting 2'-hydroxy and 6'-amino in the azithromycin A through di-tert-butyl dicarbonate so as to obtain double-protective azithromycin A; carrying out Swern oxidation to 4''-hydroxy to the double-protective azithromycin A; salifying along with trifluoroacetic acid; and synchronously removing boc t-butyloxycarbonyl to obtain the azithromycin A bitrifluoroacetic acid salt of 4''-carbonyl; and then reacting with trimethylsulfonium bromide to obtain 4''-epoxy compound; and finally carrying out nucleophilic addition on the 4''-epoxy compound by n-propylamine so as to obtain the phosphate of tulathromycin; and further neutralizing via alkaline to obtain the target compound tulathromycin; and synchronously obtaining the tulathromycin intermediate of azithromycin A bitrifluoroacetic acid salt of 4''-carbonyl.
Owner:TIANJIN ZHONGSHENG TIAOZHAN BIOTECH

Lanthanide-doped nayf4 nanocrystals, method of preparing and uses thereof

The present invention relates to a method of preparing lanthanide-doped NaYF4 nanocrystals, the method comprising: (A) providing a first solution comprising a non-coordinating solvent, a fatty acid coordinating ligand, sodium trifluoroacetate, yttrium trifluoroacetate, a first doping lanthanide trifluoroacetate and a second doping lanthanide trifluoroacetate, and a second solution comprising the non-coordinating solvent and the fatty acid coordinating ligand, the first and second solutions being substantially free of water and oxygen; (B) in an inert atmosphere, slowly adding the first solution heated at a temperature between about 100° C. and about 150° C. to the second solution heated at temperature between about 290° C. and about 330° C., thereby producing a reaction mixture containing the nanocrystals; and (C) recovering the nanocrystals from the reaction mixture. The invention also relates to lanthanide-doped uniformly shaped cubic NaYF4 nanocrystals having an average particle size of at most about 50 nm with a standard deviation of at most about 15%. Finally, the invention also relates to methods of (A) identifying or authenticating a product, (B) labelling an analyte, (C) detecting an analyte, and (D) producing a light source for the telecommunication industry using the above nanocrystals.
Owner:VALORBEC PARTNERSHIP

Complete solid-phase synthesis method for liraglutide

The invention discloses a complete solid-phase synthesis method for liraglutide. 2-Cl-TrtResin is enabled to serve as a solid-phase carrier. DIC/HOBt is enabled to serve as a condensation agent. After processing of microwave reaction technology, reaction time is shortened, and condensation efficiency is improved. According to side chain modification, novel ivDde side chain protected lysine is adopted and side chain modification synthesis is carried out. During the process, 20% piperidine is adopted to get rid of Fmoc protection until linear chain polypeptide synthesis is finished. Then, after hydrazine hydrate is adopted to get rid of ivDde protection, a side chain modification reaction is carried out. Obtained liraglutide with complete protection on the solid phase carrier is processed by trifluoroacetic acid, and crude liraglutide is obtained. After purification and freeze-drying by a C18 column, pure liraglutide is obtained. After strong negative ion salt conversion and free-drying, acetic acid liraglutide acetate is obtained. The complete solid-phase synthesis method for the liraglutide is simple in operation, short in synthesis cycle, low in production cost, few in accessory substance, high in product yield and beneficial for mass production.
Owner:宁波瑞达医药科技有限公司

Synthesis of degarelix by solid phase segment method

The invention discloses synthesis of degarelix by a solid phase segment method, wherein Fmoc-amino acid is connected with resin so that Fmoc-amino acid-resin can be obtained; a solid phase synthesis method is adopted, and the steps of orderly connecting amino acid from the end C to the end N and removing the Fmoc group are carried out, so that Fmoc protected polypeptide resin can be obtained; the method comprises the following steps of: (1) forming polypeptide resin as shown in formula III and polypeptide resin as shown in formula IV, respectively; (2) mixing the polypeptide resin as shown in formula III with 1-5% of trifluoroacetic acid (TFA), connecting L-4,5-dihydroorotate to the side chain amino of the polypeptide resin after the protecting group of the sixth amino acid residue at the end C is removed, and then removing the Fmoc group to obtain polypeptide resin as shown in formula V; removing the Fmoc group of the polypeptide resin as shown in formula IV and acetylating the polypeptide resin, thereby obtaining polypeptide resin as shown in formula VI, and then cutting to obtain segments as shown in formula VII; (3) coupling the polypeptide resin as shown in the formula V with the segments as shown in the formula VII, thereby obtaining the polypeptide resin as shown in formula II; (4) separating polypeptide on the polypeptide resin as shown in the formula II from the resin, thereby obtaining degarelix as shown in formula I.
Owner:HAINAN SHUANGCHENG PHARMA

Phellinus igniarius mycelium liquid fermentation method by utilizing fungal elicitor for improving yield of flavone of phellinus igniarius

The invention discloses a phellinus igniarius mycelium liquid fermentation method by utilizing a fungal elicitor for improving the yield of flavone of phellinus igniarius, which comprises the steps of: inoculating a fungal elicitor strain for activated culture, and then inoculating and culturing a fungal block to obtain a fungal elicitor mycelium through filtration; then drying, grinding and crushing the fungal elicitor mycelium, adding the crushed fungal elicitor mycelium into ethanol for soaking, filtering the obtained solution, collecting filter residue, orderly adding a mixed solution of chloroform and normal butanol, acetone and water into the filter residue for washing, adding trifluoroacetic acid into a dry substance after the air-drying, performing boiling water bath for 0.5 to 2 hours, then filtering the obtained solution, taking a filtrate for neutralization, standing the filtrate, using a microporous filtering film with the pore diameter between 0.4 and 5mu m to filter the filtrate for sterilization to obtain the fungal elicitor, and cryopreserving the fungal elicitor at the temperature of between 10 and 20 DEG C below zero; inoculating a phellinus igniarius strain for activated culture, and then inoculating a fungal block for fermentation culture; and adding the fungal elicitor into the phellinus igniarius to continue culturing to obtain a phellinus igniarius mycelium within 1 to 5 days of liquid fermentation culture of the phellinus igniarius. The method has simple process, low cost and remarkable effect, can greatly improve the content of the flavone of phellinus igniarius cells, and is a production method with industrialization prospect.
Owner:LUDONG UNIVERSITY

Solid phase synthetic technique for thymosin alpha1

ActiveCN101104638AAdvantages of solid phase synthesis processEasy to purifyThymopoietinsPeptide preparation methodsFluoroacetic acidAcetic anhydride
The invention relates to a solid-phase synthesis process of a thymosin alpha 1, belonging to the polypeptide solid-phase synthesis technical field. The invention comprises the following steps: a. a Fmoc-Rink Amide AM resin or a Fmoc-Rink Amide MBHA resin is used as carrier, an H2N-Rink Amide AM resin or an H2N-Rink Amide MBHA resin is obtained after deprotection of the Fmoc; b. side chain carboxyl group of Fmoc-Asp-X is connected with resin amino by the method of solid-phase synthesis to obtain the Fmoc-Asp (resin)-X; c. the left amino acid in the sequence is synthesized in solid-phase with the Fmoc strategy; d. after the amino protection group Fmoc of N terminal amino acid is removed, the N terminal amino acid is acetylated by acetic anhydride and pyridine; e. then the acetylated N terminal amino acid is cut by a cracking agent (tri fluoroacetic acid/ benzoylate sulfide/1, 2- dithioglycol/ Anisole) to obtain the thymosin alpha 1; f. crude product of the thymosin alpha 1 is prepared and separated by HPLC to obtain the pure thymosin alpha 1. The invention can increase significantly the yield of the thymosin alpha 1 and decrease the production cost, which is helpful for scale production and has better industrialization prospect.
Owner:苏州天马医药集团天吉生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products